Rhythm Pharmaceuticals Inc
NASDAQ:RYTM
Intrinsic Value
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing and commercializing peptide therapeutics for the treatment of gastrointestinal diseases and genetic deficiencie... [ Read More ]
The intrinsic value of one RYTM stock under the Base Case scenario is 25.95 USD. Compared to the current market price of 41.79 USD, Rhythm Pharmaceuticals Inc is Overvalued by 38%.
Valuation Backtest
Rhythm Pharmaceuticals Inc
Run backtest to discover the historical profit from buying and selling RYTM stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Impressive Revenue Growth Amidst Clinical Progress
2023-Q4 Earnings Call
The company reported a substantial revenue increase of 175% year-over-year, totaling $24.2 million in Q4, driving full-year revenue to $77.4 million. Despite a minor setback with a state Medicaid resulting in the loss of patient reimbursement, the firm continued to see consistent demand and prescription growth. Alongside this financial progress, promising clinical trials showed significant weight loss in pediatric patients treated with innovative therapies, with label expansion efforts underway in European markets. R&D and SG&A expenses rose in reflection of this clinical and commercial expansion.
Balance Sheet Decomposition
Rhythm Pharmaceuticals Inc
Current Assets | 308.3m |
Cash & Short-Term Investments | 275.8m |
Receivables | 14.9m |
Other Current Assets | 17.6m |
Non-Current Assets | 24.5m |
PP&E | 2.1m |
Intangibles | 7m |
Other Non-Current Assets | 15.3m |
Current Liabilities | 55.2m |
Accounts Payable | 4.9m |
Accrued Liabilities | 39.6m |
Other Current Liabilities | 10.8m |
Non-Current Liabilities | 107.8m |
Long-Term Debt | 106.1m |
Other Non-Current Liabilities | 1.6m |
Earnings Waterfall
Rhythm Pharmaceuticals Inc
Revenue
|
77.4m
USD
|
Cost of Revenue
|
-9.3m
USD
|
Gross Profit
|
68.1m
USD
|
Operating Expenses
|
-252.5m
USD
|
Operating Income
|
-184.4m
USD
|
Other Expenses
|
-321k
USD
|
Net Income
|
-184.7m
USD
|
Free Cash Flow Analysis
Rhythm Pharmaceuticals Inc
What is Free Cash Flow?
RYTM Profitability Score
Profitability Due Diligence
Rhythm Pharmaceuticals Inc's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
Score
Rhythm Pharmaceuticals Inc's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
RYTM Solvency Score
Solvency Due Diligence
Rhythm Pharmaceuticals Inc's solvency score is 74/100. The higher the solvency score, the more solvent the company is.
Score
Rhythm Pharmaceuticals Inc's solvency score is 74/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
RYTM Price Targets Summary
Rhythm Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for RYTM is 60.07 USD with a low forecast of 49.49 USD and a high forecast of 84 USD.
Ownership
RYTM Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
RYTM Price
Rhythm Pharmaceuticals Inc
Average Annual Return | 28.22% |
Standard Deviation of Annual Returns | 101.64% |
Max Drawdown | -92% |
Market Capitalization | 2.5B USD |
Shares Outstanding | 60 140 500 |
Percentage of Shares Shorted | 24.04% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing and commercializing peptide therapeutics for the treatment of gastrointestinal diseases and genetic deficiencies. The company is headquartered in Boston, Massachusetts and currently employs 140 full-time employees. The company went IPO on 2017-10-05. The firm is focused on developing treatment for genetic diseases of obesity, which are characterized by early-onset, severe obesity and an insatiable hunger (hyperphagia). The Company’s lead product candidate, IMCIVREE (setmelanotide), is a potent melanocortin-4 receptor (MC4R). IMCIVREE is developed for the treatment of rare genetic diseases of obesity. The company is focused on the melanocortin-4 receptor (MC4R) pathway, which is responsible for regulating weight and hunger. The company targets the MC4R pathway to develop therapeutics for rare genetic diseases of obesity, including proopiomelanocortin (POMC) deficiency obesity, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl syndrome (BBS), Alstrom syndrome, POMC or LEPR heterozygous deficiency obesity, Smith-Magenis syndrome, steroid receptor coactivator 1 (SRC1) deficiency obesity, MC4R deficiency obesity and SH2B adapter protein 1 (SH2B1) deficiency obesity.
Contact
IPO
Employees
Officers
The intrinsic value of one RYTM stock under the Base Case scenario is 25.95 USD.
Compared to the current market price of 41.79 USD, Rhythm Pharmaceuticals Inc is Overvalued by 38%.